Tüdőrák: vizsgálatok itt: Tajvan

In Tajvan 144 Also abroad 2733

144 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.

2. fázisTaking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Changhua, Kaohsiung City, New Taipei City, Tainan, Taipei
Életkor
18 év and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
2. fázisTaking people
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Where
Taichung, Tainan, Taipei, Zhubei
Életkor
18 év and over
People
68 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07586202
3. fázisTaking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Kaohsiung City, Taichung, Taipei
Életkor
18 év and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
3. fázisTaking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Kaohsiung City, Taichung, Taipei, Taoyuan City
Életkor
18 év and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
2/3. fázisTaking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Taichung, Tainan, Taipei, Taoyuan
Életkor
18 év and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
1/2. fázisTaking people
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Where
Taipei
Életkor
18 év and over
People
345 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00
1/2. fázisTaking people
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Where
Changhua, Taipei, Taoyuan
Életkor
18 év and over
People
450 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04165070 · EU 2023-506932-33-00
No phaseTaking people
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Where
Changhua, Taipei, Taoyuan
Életkor
18 év and over
People
1065 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04165798
3. fázisTaking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Changhua City, Changhua County, Hsinchu, Hualien City, Kaohsiung City, Taichung, Taipei
Életkor
18 év and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
3. fázisTaking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Kaohsiung City, Taichung, Tainan, Taipei, Taipei City, Taoyuan, Taoyuan City
Életkor
18 év and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Kaohsiung City, New Taipei City, Taichung, Tainan, Taoyuan
Életkor
18 év and over
People
1160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
2. fázisTaking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Taipei
Életkor
18 év and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
3. fázisTaking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Changhua, Kaohsiung City, New Taipei City, Taichung, Tainan, Taipei, Taoyuan
Életkor
18 év and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Kaohsiung City, New Taipei City, Taichung, Tainan, Taoyuan
Életkor
18 év and over
People
1160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
1/2. fázisTaking people
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
Where
Changhua, Taipei
Életkor
18 év and over
People
235 worldwide
Run by
Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00
1/2. fázisTaking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Taichung, Taipei
Életkor
18 év and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
1/2. fázisTaking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
Changhua, Chiayi City, Kaohsiung City, Taipei, Taoyuan City
Életkor
18 év and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00
3. fázisTaking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
New Taipei City, Tainan, Taipei, Taipei City
Életkor
18 év and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
2. fázisTaking people
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Where
Kaohsiung City, Taichung, Taipei, Taoyuan City
Életkor
18 év and over
People
180 worldwide
Run by
AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00
2. fázisTaking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
Életkor
18 év and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
3. fázisTaking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan City
Életkor
18 év and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
2/3. fázisTaking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Tainan, Taipei, Taoyuan
Életkor
18 év and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
3. fázisTaking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Kaohsiung City, Kaohsiung Niao Sung Dist, New Taipei City, Taichung, Taoyuan
Életkor
18 év and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
1/2. fázisTaking people
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]
Where
Taichung
Életkor
18 év and over
People
268
Run by
Daiichi Sankyo
See details and how to joinNCT07890714 · EU 2024-519729-39-00
2. fázisTaking people
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Where
Liuying, New Taipei City, Tainan, Taipei
Életkor
18 év to 95 év
People
630 worldwide
Run by
AstraZeneca
See details and how to joinNCT05061550 · EU 2023-508852-21-00